All the same, yet different – Ethnic Equality Month
Mohammed Samy, Human Pharma Marketing Team Lead from Amsterdam explains how ethnic diversity creates collective strength and sustainable growth. Read more.
Search
Human Health
Boehringer Ingelheim is dedicated to the discovery, development, manufacture and marketing of innovative health care products. Click here to learn more.
Co-creation with Communities
Making More Health has launched co-creation projects in Asia, Africa, Europe and other localities around the world with top social entrepreneurs.
Boehringer Ingelheim China for a green future
Together with all other functions, Fangya Qiang oversees the MORE GREEN programme at Boehringer Ingelheim’s Chinese locations. Click here to learn more.
Collaboration in Oncology
Oncology is a fast-moving, challenging field but with collaboration between different disciplines, we can develop the best practice care for our patients.
Our Contribution
Humanity is facing serious challenges. We believe we can always do more – for ourselves and for the generations to come. Click here to find out more.
Global poultry trends Professor David Hughes
Professor David Hughes takes us through megatrends in poultry. Poultry is booming – sustainably and in the long-term. Click here to read more.
Be green Japan
Boehringer Ingelheim's Yamagata site is gradually switching to a more sustainable energy supply. Click here to find out more information about this.
More Health Overview
Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations. Learn more.
FuturePack
Boehringer Ingelheim has built a new special machine that enables efficient and sustainable packaging of small batches. Learn more about this here.
Partnering for innovation and growth
In this interview Dr Frerich de Vries talks about why partnerships are one of the key areas of interest for Boehringer Ingelheim and more. Learn more.
Waste
Resource conservation at Boehringer Ingelheim is managed as part of an ongoing process of prevention and reduction of material usage and waste. Learn more.
Stem cells a new frontier
Stem cells may be a game changer for the development of new veterinary treatments. Click here to read this story and find out more information.
More health in vulnerable communities
Making More Health, offers expertise, network and financial support to social entrepreneurs, plus more. Read more about Making More Health here.
The Nagoya Protocol
At Boehringer Ingelheim, environmental consciousness and protection are priorities in everything we do. Read our commitments to the Nagoya Protocol.
Boehringer Ingelheim India to sustain growth momentum in 2021, focuses on partnerships in NCD management
Boehringer Ingelheim India to sustain growth momentum in 2021, focuses on partnerships in NCD management. Click here to find out more information.
Production Insights
Boehringer Ingelheim makes an important contribution to the reliable and sustainable supply of pharmaceuticals. Click here to learn and find out more.
Boehringer Ingelheim India enters into second collaboration with SIIC IIT Kanpur to support healthcare innovation
Boehringer Ingelheim India enters into second collaboration with SIIC IIT Kanpur to support healthcare innovation
Stroke
Boehringer Ingelheim developed the only licensed blood clot dissolving treatment (thrombolytic) for acute ischaemic stroke therapy, now used worldwide.
Poultry
We are proud to play a critical role in feeding the world with safe, affordable, abundant and sustainable quality poultry meat and eggs. Learn more here.
Patient Organizations
Boehringer Ingelheim’s core principles and vision guide our work with patient organisations. Learn about how we collaborate with patient organisations.
Living Independence
Boehringer Ingelheim’s corporate culture is based on values that have been applied since the company was founded in 1885. Click here to learn more.
COVID-19: Research Update
Boehringer Ingelheim stops treatment with experimental medication in study investigating benefits for severely ill patients with COVID-19. Learn more.
COVID-19 IMI2–Call 21
CARE launched to accelerate therapy development against COVID-19 and future coronavirus threats.
Our-position
12 years ago, several leading German companies including Boehringer Ingelheim came together to launch Afrika Kommt! Learn more about it here.